TY - T1的维生素D水平与残疾和脑容量在多发性硬化(S50.003) JF -神经学乔-神经病学SP - S50.003 LP - S50.003六世- 78 - 1补充AU -艾伦Mowry盟Emmanuelle Waubant首页 AU -查尔斯·麦克洛克盟Mehul Sampat AU -帕梅拉Qualley盟-罗宾·林肯盟Pierre-Antoine Gourraud AU -艾伦·伊万格丽斯塔盟也Brenneman盟Azadeh Beheshtian AU -莎拉Llufriu AU -斯蒂芬·豪泽盟-丹尼尔Pelletier Y1 - 2012/04/26 UR - //www.ez-admanager.com/content/78/1_Supplement/S50.003.abstract N2 -目的:确定维生素D与后续相关残疾进展或损失大脑体积的磁共振成像(MRI)在多发性硬化(MS)患者。背景我们已经表明,维生素D水平较高与较低的风险,后续炎症患者的临床和MRI结果复发缓和(RR)女士/临床孤立综合征(CIS)。设计/方法:史诗女士是一个纵向队列研究的加州大学,旧金山。参与者临床评估、大脑核磁共振成像和血每年吸引了。在这项研究中,我们评估基线CIS的诊断或名RRMS患者。在多变量重复测量分析调整年龄、性别、种族、吸烟状况、和使用MS治疗,年度评估他们的25 -羟基维生素D浓度与随后的残疾进展(规模扩大残疾状态)和脑容量(归一化脑实质nBPV,灰质(nGMV)和白质nWMV卷,由SIENAX)。白质病变面具了SIENAX避免像素错误分类。结果:469例中名RRMS / CIS,更高的低维生素D水平与残疾在平均四年(-0.047点低eds每10 ng / mL高维生素D, 95%可信区间[-0.091,-0.003],p = 0.037)。平均不到两年后,每个人体内25 -羟维生素D水平高出10 ng / mL与高7.0 cc nGMV(95%可信区间[2.4,11.5],p = 0.003)。每个10 ng / mL的协会高维生素D水平与nBPV不强(3.9 cc, 95%可信区间[-0.6,8.3],p = 0.088),和协会似乎并未有意义nWMV (-1.2 cc, 95%可信区间[-4.3,1.9],p = 0.44)。结论:提高维生素D水平与减少后续残疾和减少损失的灰质体积。维生素D在MS.Supported神经退化可能是一个重要因素:美国国立卫生研究院(电解加工:K23NS067055;DP: R01NS062885)、葛兰素史克和生原体Idec。披露:Mowry博士没有披露。 Dr. Waubant has received personal compensation for activities with Teva Neuroscience, Actelion, Sanofi-Aventis Pharmaceuticals, Roche Diagnostics Corporation and Biogen Idec as a speaker and/or consultant. Dr. Waubant has received research support from Biogen Idec and Sanofi-Aventis Pharmaceuticals. Dr. McCulloch has nothing to disclose. Dr. Sampat has nothing to disclose. Dr. Qualley has nothing to disclose. Dr. Lincoln has nothing to disclose. Dr. Gourraud has nothing to disclose. Dr. Evangelista has nothing to disclose. Dr. Brenneman has nothing to disclose. Dr. Beheshtian has nothing to disclose. Dr. Llufriu has nothing to disclose. Dr. Hauser has received personal compensation for activities with BioMarin, Novartis and Receptos as a consultant and serving on a scientific advisory board.Dr. Hauser has received personal compensation in an editorial capacity for the journal Annals of Neurology and Harrison's Internal Medical textbook.Dr. Hauser has received compensation for serving on the scientific advisory board of Receptos. Dr. Pelletier has received personal compensation for activities with Teva Neuroscience, Genetech, Biogen-Idec, Bayer, and Synarc Inc. Dr. Pelletier has received research support from Biogen Idec.Thursday, April 26 2012, 13:00 pm-14:45 pm ER -